Skip to main content
. 2020 Aug 10;11(8):696. doi: 10.1038/s41419-020-02783-5

Fig. 2. Hypo-Exo exerts better cardioprotective effects against myocardial injury than Nor-Exo in vitro and in vivo.

Fig. 2

a Hypo-Exo improved cell viability in H9c2 cells under normal and H/SD conditions (n = 6). b Hypo-Exo decreased apoptosis in H9c2 cells under H/SD conditions (n = 3). c Flowchart of in vivo experimental design. d Dil-labeled exosomes were injected into the infarcted heart of rats for 6 h (50 μg exosomes per rat). Representative images of post-MI heart sections stained with Dil-labeled Exo (red), α-actin (green), and DAPI (blue). The white arrow indicates that exosomes were absorbed by cardiomyocytes. e Representative echocardiographic images showing heart function among the different groups on the 28th day following MI. Quantitative analysis of left ventricular ejection fraction (LVEF) and left ventricular fraction shortening (LVFS) among the different groups (n = 6 for sham group, n = 5 for MI + PBS group, n = 6 for MI + Nor-Exo group, n = 5 for MI + Hypo-Exo group). f Masson’s trichrome-stained myocardial sections on the 28th day following MI in rats treated with sham, PBS, Nor-Exo, and Hypo-Exo. Scar tissue and viable myocardium are identified in blue and red, respectively (n = 3). Data are presented as mean ± SEM. Statistical analysis was performed with one-way ANOVA followed by Bonferroni’s correction. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.